Earnings & Valuation
This table compares Mangoceuticals and its competitors in terms of gross revenue, earnings per share, and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Mangoceuticals | $866,792.00 | -$9.21 million | -5.65 |
| Mangoceuticals Competitors | $2.39 billion | $82.32 million | 15.75 |
Mangoceuticals’ competitors have higher revenue and earnings compared to Mangoceuticals. Mangoceuticals has a lower price-to-earnings ratio than its competitors, suggesting it is more affordable in the industry.
Analyst Recommendations
This shows recent recommendations for Mangoceuticals and its competitors from MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mangoceuticals | 0 | 0 | 0 | 0 | N/A |
| Mangoceuticals Competitors | 36 | 288 | 416 | 147 | 2.76 |
Analysts believe that “Miscellaneous health & allied services, not elsewhere classified” companies have a 15.41% potential upside. Mangoceuticals is seen to have less growth potential compared to its competitors by analysts.
Profitability
This table compares Mangoceuticals and its competitors in terms of net margins, return on equity, and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mangoceuticals | -1,053.93% | -243.34% | -200.73% |
| Mangoceuticals Competitors | -816.62% | -48.14% | -36.60% |
Insider and Institutional Ownership
56.7% of Mangoceuticals shares are owned by institutional investors. Companies in the “Miscellaneous health & allied services, not elsewhere classified” category have institutional ownership of 61.8%. Company insiders hold 39.3% of Mangoceuticals shares, while the industry average is 27.3%. Strong institutional ownership shows confidence in long-term growth potential.
Volatility & Risk
Mangoceuticals has a beta of 1.76, indicating higher volatility compared to the S&P 500. Competitors have a beta of 3.97, suggesting even greater volatility than Mangoceuticals.
Summary
Competitors outperform Mangoceuticals in 9 out of 10 factors analyzed.
Mangoceuticals Company Profile
Mangoceuticals, Inc. is a company that markets men’s wellness products in the U.S. through a telemedicine platform. It offers products for erectile dysfunction and hair loss under the Mango and Grow brands, respectively. The company also markets an oral testosterone replacement therapy under the PRIME program in partnership with Marius Pharmaceuticals, LLC. Mangoceuticals, Inc. was founded in 2021 and is based in Dallas, Texas. It operates as a subsidiary of Cohen Enterprises, Inc.
Receive News & Ratings for Mangoceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Mangoceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
